Where can I find the protein concentration?

The protein concentration of each product is listed on the Certificate of Analysis. This value is determined for each individual lot and reflects the actual concentration (mg/mL) of the material you received.

Where can I find the recommended storage conditions?

Storage conditions are listed on both the product datasheet and the Certificate of Analysis. These recommendations are based on internal stability assessments and are intended to maintain protein integrity and activity.

What should I do if my product arrives warm, partially thawed, or damaged?

Please contact Athens Bioscience with your order number and lot number. Our technical support team will assist you promptly.

Where can I find the final buffer composition?

The final buffer formulation is provided on the Certificate of Analysis. This includes buffer components, pH, and whether the product was supplied as a liquid or lyophilized powder.

Apolipoprotein AIV

Name: Apolipoprotein AIV
SKU: 16-16-120104-50UG
Availability: InStock

Product Description

Role of protein in biology

Apolipoprotein A-IV (ApoA-IV), a glycoprotein synthesized predominantly in the small intestine during fat absorption, is a structural component of HDL and chylomicrons. Its four-helix bundle architecture facilitates lipid emulsification and interaction with apolipoprotein B (apoB) to promote chylomicron assembly and secretion. Postprandially, ApoA-IV dissociates from chylomicrons into the lipoprotein-free plasma fraction, where it activates lecithin-cholesterol acyltransferase (LCAT) and enhances lipoprotein lipase (LPL) activity via apoC-II, critical for triglyceride-rich lipoprotein catabolism.

Common research uses

ApoA-IV exhibits protective roles against cardiovascular disease (CVD) by inhibiting vascular inflammation through NF-κB suppression and upregulating DHCR24, an anti-inflammatory enzyme. Genetic variants like APOA4 S347 correlate with elevated coronary heart disease (CHD) risk and reduced plasma ApoA-IV levels. In metabolic regulation, ApoA-IV improves insulin sensitivity by stimulating GLUT4 translocation in adipocytes via PI3K-Akt pathways and enhances glucose-stimulated insulin secretion, with deficiencies linked to glucose intolerance. Chronic high-fat diets blunt its satiety signaling, contributing to obesity, while Roux-en-Y gastric bypass increases ApoA-IV, correlating with weight loss and improved glucose control 56.

Clinically, ApoA-IV serves as a biomarker for CHD risk and diabetes progression. Therapeutic strategies targeting its anti-inflammatory, insulinotropic, and lipid-modulating properties show promise for metabolic and cardiovascular disorders.

Common uses include lipid metabolism studies.